Comparative Study
doi: 10.1016/S0140-6736(03)14776-9.
Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
Affiliations
- PMID: 14615102
- DOI: 10.1016/S0140-6736(03)14776-9
Item in Clipboard
Comparative Study
Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
Lancet.
.
No abstract available
Comment on
-
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.Lancet. 2003 Nov 8;362(9395):1517-26. doi: 10.1016/S0140-6736(03)14738-1. Lancet. 2003. PMID: 14615106 Clinical Trial.
Similar articles
-
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.Neurology. 2003 Feb 25;60(4):729-30; author reply 729-30. doi: 10.1212/wnl.60.4.729-a. Neurology. 2003. PMID: 12601130 No abstract available.
-
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.Eur J Neurol. 2007 Mar;14(3):290-6. doi: 10.1111/j.1468-1331.2006.01639.x. Eur J Neurol. 2007. PMID: 17355549 Clinical Trial.
-
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].Ugeskr Laeger. 2015 May 11;177(20):956-60. Ugeskr Laeger. 2015. PMID: 26535431 Review. Danish.
-
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].Rev Neurol. 2012 Oct 1;55(7):421-30. Rev Neurol. 2012. PMID: 23011861 Review. Spanish.
-
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].Ugeskr Laeger. 2014 Mar 17;176(12A):V09130552. Ugeskr Laeger. 2014. PMID: 25350886 Review. Danish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
